[ad_1]
London, January 25, 2024 /PRNewswire/ — LifeArc Ventures, a company focused on investing in innovative early-stage life sciences companies, today announces updates to its portfolio.
Claire TelllowThe head of LifeArc Ventures says:: “Our investment portfolio expanded during the year and we are pleased to have been able to invest in six new companies and continue to support the growth of our existing portfolio companies, despite the challenging funding conditions in this sector. As part of LifeArc, we are able to offer companies the following services: We are excited to have additional scientific support and continue to invest in great early-stage opportunities.”
LifeArc Ventures’ portfolio expanded in 2023, investing in five companies and co-founding one new company in the therapeutics and healthtech space. We also participated in several follow-on rounds across our portfolio.
We have expanded our investment team, added two new members, and further strengthened our Early Ventures Investment Committee with the appointment of a new chair and new independent members. We are pleased to continue to benefit from their experience and advice in both biotechnology and health technology investments.
We are proud to be part of LifeArc. LifeArc provides unique access to scientific dry and wet labs and an in-house scientist talent pool, enabling us to inform decision-making and provide hands-on support to our portfolio companies. By achieving our goal of generating financial returns by investing in innovative early stage life sciences companies, we are also contributing to maintaining LifeArk as the UK’s leading medical research charity. Masu.
Accelerating investment in innovative science
Six new investments added in 2023.
we led $16 million Series A funding cambridge-Base of Maxion Therapeutics In February, we jointly invested with Monograph Capital and BGF to support the development of novel biologics targeting ion channels and G protein-coupled receptors (GPCRs) through Maxion’s KnotBody® platform. Ion channels and his GPCRs are important cell surface proteins involved in a wide range of previously untreatable diseases, including autoimmune diseases and chronic pain.
I participated in July $16 million US-based Series A affect treatment, alongside Artis Ventures, AlleyCorp, CityLight, Samsung Next, and What If Ventures. Affect offers specialized treatments for certain substance use disorders, including certain drug use disorders such as alcohol, marijuana, cocaine, and methamphetamines, as well as prescription stimulants such as ADHD medications.
In August, another exciting project came to fruition. ozro sleep With a team led by former Bose executives, it has come out of stealth and introduced its flagship product, the Ozlo Sleepbuds®. This is the first in an ecosystem of sleep solutions that use sophisticated technology and sound to unlock restorative sleep.
We look forward to discussing three of them in more detail. High interest therapeutic areas including oncology and rare diseases, and a new UK-based company focused on: Huntingdon’s Illness – During 2024.
We have ambitious investment plans, so please keep in touch with us about exciting investment opportunities.You can also contact us directly [email protected]follow us for news and activities @LifeArcVentures and LinkedIn.
Substantive portfolio progress
Three of our companies, AviadoBio, Cumulus Neuroscience, and Maxion Therapeutics, PwC UK’s Life Sciences Future 50 October Report – A great example of exceptional scientific innovation in the UK and the strength and breadth of our portfolio.
Aviad Bio began a Phase 1/2 ASPIRE-FTD clinical trial evaluating its flagship product AVB-101 in frontotemporal dementia patients with progranulin mutations in October, followed shortly by FDA IND approval and Fast Track. He received the designation and had a productive year.
Following the successful Series A, Maxion Wins £2m in Innovate UK funding and appointed industry veteran Eva Lotta-Alain As chairman.
RQ BioThe company, which we co-founded and co-funded in 2022, says its monoclonal antibody aimed at preventing COVID-19 in vulnerable patients entered clinical trials less than 12 months after its discovery. Announced. AstraZeneca’s Phase I/III study will evaluate the safety, efficacy and neutralizing activity of AZD3152 compared to a comparator for pre-exposure prophylaxis for coronavirus disease (COVID-19). AstraZeneca licensed his AZD3152 from RQ Bio. May 2022. Separately, RQ Bio and US company AbCellera have entered into a strategic collaboration to identify clinical candidates for up to three infectious disease targets, including influenza and cytomegalovirus (CMV).
closed loop medicine We have entered into a global co-development partnership with Pharmanovia, initially focused on the development and launch of a combination drug and software version of a first-line antihypertensive drug in the UK. A phased global rollout and development of additional treatments is planned.
Expansion of investment team and IC
The Early Ventures Investment Committee has been significantly strengthened with the following appointments: Deborah Harland As chairman. Debbie has an outstanding track record in the sciences of her life, including as a highly respected partner in transatlantic venture capital firm SR One and as a venture partner, and as a well-regarded board member in a number of venture-backed companies. We are proud of We also welcomed US-based companies. david van sickleHe has over 15 years of experience developing and commercializing digital health technologies and was co-founder and CEO of Propeller Health, a digital health and therapeutics company dedicated to improving the management of asthma and COPD.
John Nash He has been named an investment principal on the Ventures team. John joins us from the biotech investment team at M Ventures, where he started his career as a medical doctor and was previously an associate in the healthcare investment banking team at UBS. Matthew Lelum-Robinson He joined the company as an investment associate from LEK Consulting’s life sciences practice.
In addition, Claire Telllowhead of LifeArc Ventures, has been re-elected to the BioIndustry Association (BIA) Board of Directors for a third time.
contact address:
|
life arc |
[email protected] |
|
Claire Telllow |
|
|
Mo PR Advisory |
|
|
Mo Noonan / Jonathan Burt |
Phone number: +44 (0) 7876 444977 / 07860 361746 |
Note to editors:
About LifeArc
LifeArc is a self-funded medical research charity that has been applying early-stage science to medical treatments, including the diagnosis of antibiotic resistance and four licensed medicines, for over 25 years. Our model is built on collaboration, investing in seed and Series A stage companies through the LifeArc Ventures team, with subsequent significant investments limited to successful portfolio companies. Our venture approach focuses on investing in new translational science and technology, with the dual goal of generating economic returns for charities and positive impact for patients.
For more information, please visit www.lifearc.org or follow us on LinkedIn or Twitter (@LifeArcVentures).
Logo – https://mma.prnewswire.com/media/2326817/LifeArc_Logo.jpg
Source LifeArc
[ad_2]
Source link
